SINGAPORE – Despite a number of advantages as a site for early stage clinical trials, Asia not only lags other regions in the world but the proportion of studies it hosts is actually dropping.
HONG KONG – Marking an important shift in the way the biotech industry operates in Asia, companies are increasingly willing and eager to share information with their peers, governments and industry associations to develop new and more effective immunotherapies.
HONG KONG – A Chinese biotech company has moved its innovative rabies vaccine into human trials in Singapore, with the hope of making therapy less dependent on the assistance of immunoglobulin.
HONG KONG – South Korean pharmaceutical major Green Cross Corp. is expanding its cell therapy business to China's Guizhou Province, where the local government has welcomed the investment in an emerging new therapeutic area with great potential.
HONG KONG – A Chinese biotech company has moved its innovative rabies vaccine into human trials in Singapore, with the hope of making therapy less dependent on the assistance of immunoglobulin.
HONG KONG – South Korean pharmaceutical major Green Cross Corp. is expanding its cell therapy business to China's Guizhou Province, where the local government has welcomed the investment in an emerging new therapeutic area with great potential.
HONG KONG – Paving the way for further growth of a $2 billion sector, the CFDA has published final regulatory guidelines for biosimilars. Included are standards for research, development and evaluation. Most importantly, the CFDA also gave clear instruction on the pathway, categorization and application material needed for biosimilar registrations.
HONG KONG – Starting March 5, Japan's regulator suspended a subsidiary of Novartis AG from manufacturing or selling drugs, citing a string of unreported negative side effects patients suffered after using the company's drugs.
HONG KONG – Expansion among Chinese biotech companies China Biologic Products Inc. (CBPO) and Wuxi Pharmatech (Cayman) Inc. that recently announced full-year 2014 results has ranged from fast to too fast – with the former seeing a more than doubling of its share price and the latter watching its shares tumble over the past year.
HONG KONG – Expansion among Chinese biotech companies China Biologic Products Inc. (CBPO) and Wuxi Pharmatech (Cayman) Inc. that recently announced full-year 2014 results has ranged from fast to too fast – with the former seeing a more than doubling of its share price and the latter watching its shares tumble over the past year.
